Background. Streptococcus agalactiae, also known as Group B Streptococcus (GBS), colonizes 10-40% of women during late pregnancy and is an important cause of chorioamnionitis, or infection of the fetal membranes, and neonatal sepsis. The CDC recommends third trimester rectovaginal GBS screening, and intrapartum antibiotic prophylaxis for those testing positive. A rapid GBS diagnostic test could provide opportunities to identify GBS colonized women at the time of labor and focus the use of antibiotic therapy. Raman spectroscopy (RS) is an inelastic light scattering technique that provides biochemical spectra and has been used in vitro to characterize bacteria at the genus and species level. This study evaluated RS to identify and differentiate GBS, Escherichia coli, and Staphylococcus aureus ex vivo infection of human fetal membrane tissues.
Background. The inability to reliably discriminate bacterial, viral, and non-infectious illness has led to an epidemic of antibiotic overuse and rising rates of antimicrobial resistance. Host gene expression provides a powerful approach to distinguish infection etiologies and guide appropriate therapy. However, existing platforms for transcriptomic analysis are not amenable for clinical application. The FilmArray platform is a sample-to-answer multiplex RT-PCR system that automates transcriptomic analysis including sample preparation and data analysis. Here we report the validation of a host gene expression FilmArray test to discriminate bacterial, viral, and non-infectious etiologies of illness.
Methods. Research use only (RUO) FilmArray pouches were manufactured with 45 host response assays previously shown to discriminate bacterial, viral, and non-infectious illness. These pouches were tested on whole blood samples from 226 patients with acute respiratory illness (ARI). Using clinical adjudication as the reference standard, there were 52 bacterial, 100 viral, and 75 non-infectious cases. Quantification cycles were recorded for each assay and normalized to an internal control. A logistic regression model generated probabilities of each condition, which were used to classify subjects.
Results. Beginning with 100 µL of blood, the FilmArray host response panel provided results in ~45 minutes from sample to answer. Overall accuracy for bacterial ARI relative to clinical adjudication was 85% with an area under the receiver operating characteristic curve (AUC) of 0.92. Accuracy and AUC for viral infection were 85% and 0.91, respectively. Ill patients without infection were correctly identified 86% of the time with an AUC of 0.88.
Conclusion. These results show that the FilmArray system can rapidLy measure host gene expression to accurately discriminate bacterial, viral, and non-infectious illness. The development of such a system creates a new option to mitigate inappropriate antibiotic use. It also presents opportunities to use host gene expression as a diagnostic modality for a variety of disease states.
Disclosures Background. Procalcitonin is a hormone precursor that has been identified as a marker for bacterial infections. Procalcitonin increases as the body mounts an inflammatory response against infection, then returns to its normal range once the response subsides. Studies have shown that reduced procalcitonin levels may support antibiotic discontinuation. The purpose of this study was to determine how procalcitonin is being utilized at facilities within a large health system.
Methods. From August 1, 2016 through July 31, 2017 facilities with a minimum of 30 procalcitonin levels were assessed. Patients who received antibiotics, with and without procalcitonin levels, were evaluated. The primary outcome was the frequency of multiple procalcitonin levels drawn 24-72 hours apart. Secondary analysis included baseline procalcitonin timing, antibiotic discontinuation based on procalcitonin thresholds (<0.5 or 80% reduction from a peak level), and monitoring patterns related to outcomes such as hospital length of stay (LOS), intensive care unit LOS, antibiotic duration of therapy, and hospital-onset Clostridium difficile infections. Data were
